Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success
Z Ušiaková, V Mikulova, D Pinterova, M Brychta… - in vivo, 2014 - iv.iiarjournals.org
Circulating tumor cells (CTCs) are an independent prognostic factor for patients with
metastatic breast cancer (MBC). However, the role of CTCs in early breast cancer …
metastatic breast cancer (MBC). However, the role of CTCs in early breast cancer …
Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success.
Z Ušiaková, V Mikulová, D Pintérová… - In Vivo (Athens …, 2014 - europepmc.org
Results CTC positivity was described in 35% of patients with early breast cancer without
detected metastases before neoadjuvant chemotherapy; similarly, a 26% positivity rate was …
detected metastases before neoadjuvant chemotherapy; similarly, a 26% positivity rate was …
[PDF][PDF] Circulating Tumor Cells in Patients with Breast Cancer: Monitoring Chemotherapy Success
Z UŠIAKOVÁ, V MIKULOVÁ, D PINTÉROVÁ… - in vivo, 2014 - researchgate.net
" Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland
rate decreased to 5% in the neoadjuvant group, to 13% in the adjuvant group and to 12% in …
rate decreased to 5% in the neoadjuvant group, to 13% in the adjuvant group and to 12% in …
[PDF][PDF] Circulating Tumor Cells in Patients with Breast Cancer: Monitoring Chemotherapy Success
Z UŠIAKOVÁ, V MIKULOVÁ, D PINTÉROVÁ… - in vivo, 2014 - iv.iiarjournals.org
Circulating tumor cells (CTCs) are an independent prognostic factor for patients with
metastatic breast cancer (MBC). However, the role of CTCs in early breast cancer …
metastatic breast cancer (MBC). However, the role of CTCs in early breast cancer …
[PDF][PDF] Circulating Tumor Cells in Patients with Breast Cancer: Monitoring Chemotherapy Success
Z UŠIAKOVÁ, V MIKULOVÁ, D PINTÉROVÁ… - in vivo, 2014 - academia.edu
" Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland
rate decreased to 5% in the neoadjuvant group, to 13% in the adjuvant group and to 12% in …
rate decreased to 5% in the neoadjuvant group, to 13% in the adjuvant group and to 12% in …
Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success
Z Ušiaková, V Mikulová, D Pintérová… - In vivo (Athens …, 2014 - pubmed.ncbi.nlm.nih.gov
Circulating tumor cells (CTCs) are an independent prognostic factor for patients with
metastatic breast cancer (MBC). However, the role of CTCs in early breast cancer …
metastatic breast cancer (MBC). However, the role of CTCs in early breast cancer …
[PDF][PDF] Circulating Tumor Cells in Patients with Breast Cancer: Monitoring Chemotherapy Success
Z UŠIAKOVÁ, V MIKULOVÁ, D PINTÉROVÁ… - in vivo, 2014 - academia.edu
" Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland
rate decreased to 5% in the neoadjuvant group, to 13% in the adjuvant group and to 12% in …
rate decreased to 5% in the neoadjuvant group, to 13% in the adjuvant group and to 12% in …